Acadian Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Acadian Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,827	Closed	-$94K	–	1900
2022 Q2	$94K	Buy	+31,827	New	+$76K	﹤0.01%	1370
2020 Q2	–	Sell	-611,297	Closed	-$906K	–	2371
2020 Q1	$906K	Buy	611,297 +198,002	+48%	+$332K	0.01%	825
2019 Q4	$810K	Buy	+413,295	New	+$1.55M	﹤0.01%	936
2018 Q2	–	Sell	-33,802	Closed	-$439K	–	1884
2018 Q1	$439K	Buy	+33,802	New	+$420K	﹤0.01%	891
2017 Q2	–	Sell	-29,969	Closed	-$129K	–	1632
2017 Q1	$129K	Buy	+29,969	New	+$86K	﹤0.01%	1101
2015 Q2	–	Sell	-30,383	Closed	-$211K	–	1528
2015 Q1	$211K	Buy	+30,383	New	+$292K	﹤0.01%	914

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Acadian Asset Management's CBAY Position: Q3 2022 in Review

Acadian Asset Management sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 31,827 shares — an estimated $94K sold.

Acadian Asset Management first reported a position in CBAY in Q1 2015 and held it in 6 quarters. The position peaked at $906K in Q1 2020. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

Acadian Asset Management reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
Acadian Asset Management sold 31,827 Cymabay Therapeutics shares in Q3 2022, an estimated $94K.
Acadian Asset Management first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 6 quarters.
Acadian Asset Management's Cymabay Therapeutics position peaked at $906K in Q1 2020.
100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Acadian Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.